Waters Parkerson & Co’s AbbVie ABBV Stock Holding History

Waters Parkerson & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.44M	Buy	5,719 +720	+14%	+$155K	0.07%	94
2026 Q1	$1.09M	Sell	4,999 -25	-0.5%	-$5.55K	0.06%	97
2025 Q4	$1.15M	Sell	5,024 -17	-0.3%	-$3.87K	0.06%	96
2025 Q3	$1.17M	Hold	5,041	–	–	0.06%	96
2025 Q2	$936K	Hold	5,041	–	–	0.05%	103
2025 Q1	$1.06M	Sell	5,041 -961	-16%	-$187K	0.06%	98
2024 Q4	$1.07M	Sell	6,002 -889	-13%	-$163K	0.06%	96
2024 Q3	$1.36M	Hold	6,891	–	–	0.07%	91
2024 Q2	$1.18M	Sell	6,891 -119	-2%	-$19.7K	0.06%	88
2024 Q1	$1.28M	Sell	7,010 -28	-0.4%	-$4.83K	0.07%	88
2023 Q4	$1.09M	Buy	7,038 +419	+6%	+$61.1K	0.06%	90
2023 Q3	$987K	Sell	6,619 -262	-4%	-$38.5K	0.06%	93
2023 Q2	$927K	Hold	6,881	–	–	0.05%	94
2023 Q1	$1.1M	Sell	6,881 -475	-6%	-$72.6K	0.06%	89
2022 Q4	$1.19M	Buy	7,356 +600	+9%	+$92K	0.07%	87
2022 Q3	$907K	Hold	6,756	–	–	0.06%	92
2022 Q2	$1.03M	Buy	6,756 +200	+3%	+$30.6K	0.07%	89
2022 Q1	$1.06M	Buy	6,556 +128	+2%	+$18.6K	0.06%	91
2021 Q4	$870K	Hold	6,428	–	–	0.05%	92
2021 Q3	$693K	Hold	6,428	–	–	0.04%	109
2021 Q2	$724K	Hold	6,428	–	–	0.04%	105
2021 Q1	$696K	Sell	6,428 -500	-7%	-$53.5K	0.04%	102
2020 Q4	$742K	Buy	6,928 +987	+17%	+$94.8K	0.05%	93
2020 Q3	$520K	Buy	5,941 +37	+0.6%	+$3.48K	0.04%	105
2020 Q2	$580K	Hold	5,904	–	–	0.05%	100
2020 Q1	$450K	Buy	5,904 +2,500	+73%	+$213K	0.04%	96
2019 Q4	$301K	Hold	3,404	–	–	0.02%	132
2019 Q3	$258K	Sell	3,404 -1,600	-32%	-$110K	0.02%	140
2019 Q2	$364K	Sell	5,004 -25	-0.5%	-$1.97K	0.03%	123
2019 Q1	$405K	Hold	5,029	–	–	0.03%	108
2018 Q4	$464K	Hold	5,029	–	–	0.04%	100
2018 Q3	$476K	Buy	5,029 +1,600	+47%	+$152K	0.04%	108
2018 Q2	$318K	Hold	3,429	–	–	0.03%	123
2018 Q1	$325K	Hold	3,429	–	–	0.03%	129
2017 Q4	$332K	Hold	3,429	–	–	0.03%	129
2017 Q3	$305K	Sell	3,429 -500	-13%	-$38.1K	0.03%	134
2017 Q2	$285K	Hold	3,929	–	–	0.03%	136
2017 Q1	$256K	Hold	3,929	–	–	0.02%	142
2016 Q4	$246K	Buy	3,929 +425	+12%	+$25.9K	0.02%	146
2016 Q3	$221K	Hold	3,504	–	–	0.02%	147
2016 Q2	$217K	Hold	3,504	–	–	0.02%	139
2016 Q1	$200K	Hold	3,504	–	–	0.02%	138
2015 Q4	$208K	Buy	+3,504	New	+$202K	0.02%	134
2015 Q3	–	Sell	-4,511	Closed	-$303K	–	128
2015 Q2	$303K	Sell	4,511 -2,737	-38%	-$179K	0.04%	113
2015 Q1	$424K	Sell	7,248 -100	-1%	-$6.04K	0.05%	109
2014 Q4	$481K	Hold	7,348	–	–	0.06%	102
2014 Q3	$424K	Hold	7,348	–	–	0.05%	104
2014 Q2	$415K	Sell	7,348 -466	-6%	-$24.4K	0.05%	104
2014 Q1	$402K	Hold	7,814	–	–	0.05%	104
2013 Q4	$413K	Hold	7,814	–	–	0.05%	100
2013 Q3	$350K	Sell	7,814 -1,800	-19%	-$79.8K	0.05%	102
2013 Q2	$397K	Buy	+9,614	New	+$420K	0.06%	93

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Waters Parkerson & Co's ABBV Position: Q2 2026 in Review

Waters Parkerson & Co increased its AbbVie (ABBV) stake by 14% in Q2 2026, buying an estimated $155K and bringing the position to 5,719 shares worth $1.44M. The position accounts for 0.07% of the portfolio, ranked #94.

Waters Parkerson & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 2,850 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Waters Parkerson & Co held 5,719 shares of AbbVie worth $1.44M as of Q2 2026.
Waters Parkerson & Co bought 720 AbbVie shares in Q2 2026, an estimated $155K.
AbbVie made up 0.07% of Waters Parkerson & Co's portfolio in Q2 2026, its #94 holding.
Waters Parkerson & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
2,850 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Waters Parkerson & Co's 13F filing for Q2 2026, filed 30 Jul 2026.